From AI Activity to a Board-Defensible AI Strategy
Eularis helps pharmaceutical, biotech, and large healthcare leaders move from fragmented AI activity to a strategy that can be defended in the boardroom, underwritten by finance, and executed by the organisation.
Most organisations do not need more AI activity. They need a clearer path.
Most pharmaceutical, biotech, and large healthcare organisations already have meaningful AI activity underway.
Pilots are running. Vendors have been signed. Dashboards exist. Internal enthusiasm is genuine. Some use cases are even producing results.
What is often missing is a strategy that can survive board, executive, finance, and procurement scrutiny.
The harder questions remain unanswered:
• Which initiatives are tied to meaningful business, clinical, or operational value?
• Where is fragmentation creating drag, duplication, or risk?
• What should be prioritised, redesigned, or stopped entirely?
• What governance is required before scale is even responsible?
• What is the financial case the board will actually fund?
• What will it take to move from AI activity to a strategy that can be defended, funded, and executed?
That is the gap Eularis is built to close.
Our primary focus is pharmaceutical and biotech. We also work with large hospital networks and health systems facing a strategically identical problem in a different operating environment: AI activity that has outpaced the strategic architecture required to make it coherent, governable, and accountable.
Trusted in environments where AI decisions must hold up under scrutiny
Eularis has been advising life sciences organisations on AI strategy since 2003 — before AI was an industry agenda item, and long before it became a board agenda item.
Our work is designed for environments where AI decisions need to withstand:
• executive and board challenge
• governance, regulatory, and privacy requirements that cannot be bolted on later
• cross-functional complexity and competing stakeholder priorities
• finance and procurement review
• the pressure to demonstrate measurable value, not strategic intent
We have supported global pharmaceutical organisations, biotech firms, and large US and international hospital networks facing the same underlying problem: AI activity without strategic coherence, and pressure from leadership to fix it before more time and budget disappear into disconnected work.
Three ways to work with Eularis on Strategy
The three engagements below are designed to reduce uncertainty in stages. Each is a complete piece of work in its own right. Each can stand alone, or feed naturally into the next.
AI Strategy Diagnostic Sprint
AI Strategy Diagnostic Sprint
You leave with
Board-Defensible AI Strategy Assessment
Board-Defensible AI Strategy Assessment
You leave with
AI Strategic Blueprint
AI Strategic Blueprint
You leave with
How the engagement ladder works
The three engagements are designed to reduce uncertainty in stages, so leadership commits the right level of effort to the right decision.
The Diagnostic Sprint identifies where the problem sits and how serious it is.
The Strategic Assessment evaluates the problem in depth, defines the opportunity space, and begins shaping the financial logic.
The Blueprint builds the full strategy, financial case, governance architecture, vendor direction, and execution path.
Not every organisation needs to start at the same point.
• Some need a fast, defensible diagnosis.
• Some need a deeper strategic evaluation before they will commit to a full programme.
• Some are already clear on the problem and ready to build the full Blueprint.
If you are unsure where to begin, we can help you determine the right entry point quickly – without obligation.
Built for complex, regulated environments
Our methodology is shaped by the realities that determine whether AI succeeds in pharmaceutical companies, biotech firms, and large healthcare organisations — not the realities of industries where the cost of being wrong is lower.
That includes:
• governance, regulatory, and privacy requirements that cannot be retrofitted
• multiple stakeholder groups with different priorities, incentives, and decision rights
• executive, board, finance, and procurement scrutiny on every meaningful investment
• adoption friction in risk-aware, evidence-driven organisational cultures
• the requirement to connect every AI investment to measurable business, clinical, or operational value
The setting differs across pharma, biotech, and large hospital networks. The strategic challenge is consistently familiar — and the discipline required to solve it is the same.
Where this work applies
Pharmaceutical and biotech organisations and life science agencies
Our core work. Eularis has built AI strategy across more than 1,000 pharmaceutical AI engagements, connecting AI to the commercial, medical, market access, R&D, and operational decisions that determine revenue protection, pipeline replacement, and competitive position.
Large hospital networks and health systems
The same strategic logic applies in large hospital networks facing fragmented AI activity across revenue cycle, clinical operations, documentation, scheduling, population health, and patient experience — alongside the governance, privacy, clinician adoption, and vendor proliferation challenges that come with scale.
Different operating environment. Different stakeholders. The same underlying challenge: AI activity that has outpaced strategic coherence, and leadership that needs a defensible basis for what to fund, what to stop, and what to sequence next.
Why Eularis - and why the approach is different
Eularis has been building AI strategy in life sciences and healthcare since 2003. That depth shapes how we work.
We do not start with tools.
We do not confuse activity with progress.
We do not import generic enterprise AI playbooks into regulated environments and hope they hold.
We build vendor-neutral, board-defensible AI strategies grounded in business priorities, financial logic, governance realities, and the implementation constraints that determine whether a strategy survives contact with the organisation.
That is why pharmaceutical, biotech, and healthcare leaders come to us when they need more than a slide deck – when they need a strategy that finance will underwrite, the board will approve, and the organisation can actually execute.
Is your current AI strategy built to hold up in a board room?
A measured first step, or a full strategic engagement
Not every organisation is ready for the same level of commitment, and not every problem needs the same depth of work to solve.
That is why the engagement ladder exists. You can start with a focused diagnosis, move into a deeper strategic assessment, or begin with the full Blueprint if the need is already clear.
If you are unsure where to begin, we will help you determine the right entry point quickly.
The organisations that have trusted Eularis with their AI
Every Eularis AI Strategic Output is personally overseen by Dr. Andrée Bates
- Dr. Andrée Bates has spent over two decades at the precise intersection of pharmaceutical strategy and artificial intelligence — originating AI strategy methodology for this industry before it became a mainstream business agenda.
She has personally led AI strategic programmes for numerous top-tier pharmaceutical organisations across clinical development, medical affairs, market access, and commercial operations — and has lectured on pharmaceutical AI and healthcare innovation at INSEAD, Henley Business School, Imperial College London, Fordham University’s Gabelli School of Business, Northwestern University, and Northeastern University. - She brings two things that are rarely found in the same person: the strategic intelligence to design an AI programme that holds up to board scrutiny, and the implementation experience to know exactly where such programmes succeed and where they quietly fail.
- Every strategies that Eularis delivers reflects both.
Before your next board conversation on AI, ask yourself:
- Can you name the five to ten decisions that will most determine your organisation’s revenue performance over the next three years — and articulate precisely how AI is improving each of them?
- If your board asked you to justify your AI investment in terms of projected financial return by initiative, could you answer with confidence?
Are your AI efforts across commercial, medical, R&D, and market access aligned to the same strategic priorities — or are they optimising each function independently? - Do you have a governance architecture designed specifically for pharma’s regulatory environment — or a generic enterprise AI framework adapted from another industry?
- Is your organisation building AI capability that will compound over time — or running pilots that impress in steering committees and disappear quietly afterwards?
- While you are working through these questions, are your closest competitors already working with someone who has answered them
If any of these questions expose uncertainty, that is not a reflection of your organisation’s commitment to AI. It is a reflection of the gap that exists in almost every pharmaceutical company we speak to — between AI activity and AI strategy. That gap is closeable. Closing it is exactly what the Eularis AI Strategic Blueprint is designed to do.